

EUROPEAN MICROBIOME CONGRESS 2015

"Looking to the future, I can imagine in 15 years' time, the goal will be to look at a person's microbes and ensure the right balance is there and make adjustments if necessary to keep that person in optimal health."

-Professor George Weinstock, Geneticist,
Washington University

18-19 November 2015 • Millennium Hotel Gloucester, London, UK

2015 EVENT PROGRAMME

Join us in November to network with and learn from some of the best scientists from academia and industry all working to translate their disease insights into therapeutics.



John Cryan
Professor & Chair, Dept Anatomy
& Neuroscience & Principal
Investigator
APC, University College Cork



Harry Sokol
Gastroenterology Department
**Saint-Antoine Hospital, Paris,
France**



Max Nieuwdorp
Professor in Internal Medicine
and Diabetes, AMC, Amsterdam,
the Netherlands, Visiting
Professor
Gothenborg University



Jeroen Raes
Professor, Dept of Microbiology
and Immunology VIB lab for
Bioinformatics and (eco-)
systems biology
KULeuven



Fiona Powrie
Professor & Director
**Kennedy Institute of
Rheumatology, University of
Oxford, UK**



Manimozhiyan Arumugam
Group Leader and Associate
Professor at the **Novo Nordisk
Foundation Center for Basic
Metabolic Research University
of Copenhagen**

TOPICS INCLUDE:

- The patient interface, legal, ethics and social implications in microbiome research
- Sequencing and bioinformatics of the human microbiome, how we are using data
- Venture capital investment opportunities
- Commercialising the microbiome: Developing business relationships between academic research, pharma and business ventures
- Bringing live microbial products to market, looking at issues of IP and regulatory approaches
- Pharma investment and collaboration
- FMT and C Dif update

Media Partners:





The Human Microbiome Market is expected to reach \$658 million by 2023 from \$294 million in 2019 growing at a CAGR of 22.3% during the forecast period (2019-2023)

Dear Colleague,

As you already know, the Human Microbiome has a well-documented and significant impact on human health and well-being. The advances in next generation sequencing technologies have aided scientific research in connecting an imbalanced microbiome to conditions as diverse as cancer, pulmonary, metabolic and inflammatory disease.

Despite the recency of much of this research numerous applications are rapidly emerging. The strong evidence that FMT is spectacularly efficacious in treating certain infectious diseases and the perception that the microbiome is uniquely manipulable is proving very exciting for countless global biotech start-ups, pharma and industry alike.

Collaborations and research consortia are underway around the world surveying human microbiota at different body sites, characterising them, understanding their interactions with their host, their cause and effect role in diseases, and designing potential therapeutic or dietary interventions.

The European Microbiome Congress is the first in a global series which will provide a collaborative platform to help accelerate the translation of microbiome research at many different body sites into therapeutic targets and diagnostics and to discuss challenges like the lack of centralised governance standards and leadership plus the need for communication and information with patients.

We invite you to join us in London this November to meet, learn from and network with researchers and industry who are working hard to translate their research into drug development that will strengthen or emulate bacteria so clearly and decisively that it can be affirmed by government drug regulators. Whilst no on the shelf therapeutics exist yet, links between humans and bacteria are said by many in this field to be on the cusp of being a legitimate regulated medical business – and it is a rare opportunity to be a part of this exciting event.

Book early to save on tickets by going online at www.microbiomecongress.com or by calling us at +44 (0)20 3696 2920. We look forward to welcoming you in November!

Best,



Sarah Clayton
Managing Director
Kisaco Research

ADDITIONAL TOPICS WE'LL BE DISCUSSING ONSITE:

- An overview of the human microbiome project
- Integrated omic analyses: including concomitant metagenomics, metatranscriptomics, metaproteomics and metabolomics
- Case studies: The microbiome and its role in IBD, obesity, immunity, diabetes and cancer
- Potential for Microbiota-directed therapies in IBS
- Skin microbiome – acne, eczema and wound health
- Oral microbiome
- Impact of preterm birth prevention and management strategies on the vaginal microbiome
- The lung microbiome and commercialising potential diagnostic and therapeutic treatments
- The microbiome-gut-brain axis and impact on behaviour
- Personalised nutrition and developing products using microbiome research
- Impact of specific nutrients on the early life window
- The development of next generation probiotics, opportunities and challenges shaping applications

ABOUT KISACO RESEARCH



Kisaco Research works with the early adopters and

leaders of growth markets in driving their respective industries forward and in providing the right knowledge, learning and social opportunities to stimulate business growth quickly and effectively.

Kisaco Research produces, designs and hosts B2B industry conferences and exhibitions. Our platforms are neutral, so that our attendees get the right information from the most relevant people. Our level of research ensures the topics and products we offer are of utmost relevance and timeliness; our 30+ years of combined experience in the event industry means we have an unmatched level of strategic social engineering onsite.

Join our conferences to ensure you benefit from the high-quality knowledge, learning and networking opportunities. **Find out more about our upcoming events by emailing events@kisacoresearch.com.**



Hear from the Experts: The European Microbiome Congress

2015 SPEAKER FACULTY



**BERNARD
BERGER**

Senior Scientist
**Nestlé Research Center
in Nutrition and Health
Research**



BRIAN JONES

Head of Research
Development
**Queen Victoria Hospital
NHS Foundation Trust**



**DAVID A
MACINTYRE**

Lecturer in Reproductive
Systems Medicine
**Institute of Reproductive
and Developmental
Biology, Imperial College**



**ALAN
W. WALKER**

Rowett Institute of
Nutrition and Health
**University of
Aberdeen, UK**



**MANIMOZHIAN
ARUMUGAM**

Group Leader and
Associate Professor at the
**Novo Nordisk Foundation
Center for Basic
Metabolic Research
University of Copenhagen**



EGIJA ZAURA

Associate Professor,
Oral Microbial Ecology,
Department of
Preventive Dentistry,
**Academic Centre for
Dentistry Amsterdam
(ACTA)**



**GIOVANNI
CAMMAROTA**

Associate Professor
of Internal Medicine,
**School of Medicine and
Surgery of the Catholic
University in Rome**



HARRY SOKOL

Gastroenterology
Department
**Saint-Antoine Hospital,
Paris, France**



HELEN KETTLE

Mathematical Modeller
**Biomathematics and
Statistics Scotland,
Edinburgh**



**HERMIE J.M.
HARMSEN**

Associated Professor
**University Medical
Center Groningen**



JAMES KINROSS

Senior Lecturer in
Colorectal Surgery
**Imperial College
London**



**JANNEKE
VAN DE WIJGERT**

Clinical Epidemiologist,
Professor at the
**Institute of Infection
and Global Health
University of Liverpool**



JEROEN RAES

Professor, Dept of
Microbiology and
Immunology
VIB lab for
Bioinformatics and
(eco-)systems biology
KULeuven



**JOHAN E.T.
VAN HYLCKAMA
VLIEG**

Senior Director
Microbiome - Health &
Nutrition Division
Chr. Hansen



JOHN CRYAN

Professor & Chair,
Dept Anatomy &
Neuroscience, &
Principal Investigator
**APC, University
College Cork**



MATTHEW HENN

SVP, Head of
Drug Discovery &
Bioinformatics
Seres Therapeutics



MAX NIEUWDORP

Professor in Internal Medicine and Diabetes, AMC, Amsterdam, the Netherlands, Visiting Professor
Gothenborg University



PAUL COTTER

Principal Research Officer, Teagasc Food Research Centre & Principal Investigator,
APC



PAUL WILMES

Associate Professor of Systems Ecology
Luxembourg Centre for Systems Biomedicine of the University of Luxembourg



ERAN SEGAL

Associate Professor, Department of Computer Science and Applied Mathematics
Weizmann Institute of Science



FIONA POWRIE

Professor & Director
Kennedy Institute of Rheumatology, University of Oxford, UK



FRANK NESTLE

Professor & NIHR Senior Investigator
St. John's Institute of Dermatology, King's College London and Guy's & St. Thomas' Hospitals



R. ANTHONY WILLIAMSON

Head of Technology, Janssen Prevention Center
Janssen Pharmaceutical Companies of Johnson & Johnson



RUTH ANN LUNA

Director, Medical Metagenomics, Texas Children's Microbiome Center, **Texas Children's Hospital** & Assistant Professor
Baylor College of Medicine



SASHA ZHERNAKOVA

Assistant Professor & Rosalind Franklin Fellow
University of Groningen



WILLIAM COOKSON

Professor of Genomic Medicine and Head of Respiratory Sciences
Imperial College London



PETER G. MCLEAN

Scientific Director, GI Drug Discovery Unit
Takeda Pharmaceuticals International



ALASTAIR KENT OBE

Director
Genetic Alliance UK




FIONA COPELAND

Chairman of the
PCD Family Support Group



AILSAS HART

Director IBD Unit and Sub-Dean, St Mark's Hospital and Senior Clinical Lecturer, Department of Surgery and Cancer
Imperial College, London



In order to assess such a role we use studies involving, germ free mice and early-life microbiota manipulations and finally probiotic administration in adulthood. We assess neurochemical, molecular and behavioural effects following these manipulations. Our data show that the gut microbiota is essential for normal stress, antidepressant and anxiety responses. Moreover, microbiota is essential for social cognition and may play a role in autism-related symptomatology. Finally, there are critical time-windows early in life when the effects of microbiota on brain and behaviour appear to be more potent. Manipulation of the microbiota in early life by caesarean delivery, antibiotics or stress leads to long-lasting effects on brain and behavior. Such data offer the enticing proposition that specific modulation of the enteric microbiota by dietary means may be a useful "psychobiotic"-based strategy for both stress-related and neurodevelopmental disorders ranging from depression to autism.

John Cryan, Professor & Chair, Dept Anatomy & Neuroscience, & Principal Investigator, **APC, University College Cork**

of GI issues remains difficult in the ASD population and in particular the children with limited verbal communication. The development of stool-based biomarkers would represent a vital tool for both physicians and children with ASD. Microbiome characterization of GI specimens in children with autism will be discussed and compared to unaffected siblings, healthy children, and children with functional GI disorders. The identification of pathophysiologic mechanisms that link disturbances in the microbiome-gut-brain axis with disease phenotypes in individuals with ASD will also be addressed.

Ruth Ann Luna, Director, Medical Metagenomics, Texas Children's Microbiome Center, Texas Children's Hospital & Assistant Professor, **Baylor College of Medicine**

16:05 **The Microbiome-Gut-Brain axis in autism**

The microbiome-gut-brain axis has been implicated in behavioral disorders as well as functional gastrointestinal (GI) disorders. While GI symptoms are a significant comorbidity in children with autism spectrum disorder (ASD) and may contribute to problem behaviors, microbiome studies in individuals with autism are hampered by multiple confounders that have yielded conflicting results. Consequently, there is growing interest in defining the role of the microbiome in ASD development, especially in early childhood when establishment of the gut microbiome and manifestations of clinical ASD symptoms occur concurrently. The identification

16:30 **Modelling the emergent dynamics and major metabolites of the human colonic microbiota**

We present here a first attempt at modelling microbial dynamics in the human colon incorporating both variation between people and adaptation to environmental change. The model is shown to reproduce many of the observed changes in major phylogenetic groups and key metabolites in response to a one unit pH shift in experimental continuous flow fermentors inoculated with human faecal microbiota.

Biomathematics and Statistics Scotland (BioSS) is formally part of The James Hutton Institute (JHI), a registered Scottish charity No. SC041796 and a company limited by guarantee No. SC374831.

Helen Kettle, Mathematical Modeller, **Biomathematics and Statistics Scotland, Edinburgh**

17:10 **Close of Conference**



The European Microbiome Congress

MEDIA PARTNERS



Genetic Engineering & Biotechnology News • www.genengnews.com

Genetic Engineering and Biotechnology News (GEN) is the longest-running, most widely read, and largest circulated global biotechnology news publication. Published 21 times a year and recently redesigned to focus on Biobusiness, OMICS, Drug Discovery, Bioprocessing, and Translational Medicine, GEN reports on key news developments and technology trends in the bioindustry.



Technology Networks • www.technologynetworks.com

Technology Networks is an internationally recognised, online publisher that provides access to the latest scientific news, products, research, videos and posters. Our global community is made up of over 300,000 researchers and scientific professionals from the life science, drug discovery and analytical arenas. Our portfolio of 30 communities are available free of charge on TechnologyNetworks.com

INTERESTED IN SPONSORSHIP OPPORTUNITIES?

Far from the typical 'meet-and-greet' exhibition experience, you – as a sponsor or exhibitor – will be positioned as a partner of the event with a focus on the benefits of your product and brand, rather than just a name on an exhibition list.

With our extensive marketing experience and strategy, your partnership with the conference will grant you

a sponsorship package that is an extension and enhancement of your current marketing and branding efforts.

Ask us about the different ways you can get involved. Contact **Myran Balasingham** to find out more about each package by emailing at events@kisacoresearch.com or by calling **+44 (0)20 3696 2920**.



VENUE & ACCOMMODATIONS



MILLENNIUM GLOUCESTER HOTEL

4-18 Harrington Gardens
London, SW7 4LH
United Kingdom
T. +44 (0) 20 7373 6030

Kisaco Research is pleased to announce that all attendees of the European Microbiome Congress will be able to access an exclusive group rate. Check back soon for full details on how to book. Please note that hotel and travel are not included in conference fees.

PRICING INFORMATION

DISCOUNT DEADLINE	STANDARD RATES FOR INDUSTRY	REDUCED RATES FOR ACADEMICS, STUDENTS & POST-DOCTORAL RESEARCHERS*
August 15, 2015	£499 + VAT	£199 + VAT
Pay at the Door	£795 + VAT	£399 + VAT

FEATURE	STANDARD PASS (MAIN CONFERENCE ONLY)	STANDARD PASS (MAIN CONFERENCE ONLY)
2-Day Main Conference	✓	✓
Daily Lunches & Refreshments	✓	✓
Post-Show Access to Presentations	✓	✓
Welcome Networking Reception	✓	✓
Poster Sessions	✓	✓
Complimentary Articles and Content	✓	✓

BOOK A TEAM TO SAVE MORE!	
Bring a Colleague...	Save an Additional 10% Off
Book a Team of 3+	Save an Additional 15% Off
Book a Team of 5+	Save an Additional 20% Off

Payment Terms for the Microbiomes Conference::

- * You must email us a signed letter from the Hospital / Clinic Supervisor or University / Laboratory with confirmation of your status upon payment
- All Prices are in GBP
- All Early Bird discount prices, including Group Discounts, must be paid in full by deadlines provided above.
- All discount offers cannot be combined with any other offer, except for the Group Discount, which you can apply to any Early Bird Discount.
- Please view our Cancellation Policy.
- All Price exclude GB VAT of 20% (GB201759917)

YES, PLEASE REGISTER ME:

Attendee Information:

Name: _____

Company: _____

Phone: _____ Email: _____

Payment Information:

Visa MasterCard American Express Discover

Credit Card Number: _____ Expiration Date: ____/____/____ Security Code: _____

Card Holder's Name: _____

Signature: _____

Billing Address on Card: _____